CN102559614A - Classical swine fever vaccine and preparation method thereof - Google Patents
Classical swine fever vaccine and preparation method thereof Download PDFInfo
- Publication number
- CN102559614A CN102559614A CN2012100056192A CN201210005619A CN102559614A CN 102559614 A CN102559614 A CN 102559614A CN 2012100056192 A CN2012100056192 A CN 2012100056192A CN 201210005619 A CN201210005619 A CN 201210005619A CN 102559614 A CN102559614 A CN 102559614A
- Authority
- CN
- China
- Prior art keywords
- silkworm
- recombinant
- swine fever
- bmgp64
- baculovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccines Drugs 0.000 title claims abstract description 45
- 208000001726 Classical Swine Fever Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 241000255789 Bombyx mori Species 0.000 claims abstract description 46
- 241000701447 unidentified baculovirus Species 0.000 claims description 50
- 241000700605 Viruses Species 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 101700037939 DNAPR Proteins 0.000 claims description 8
- 101700030310 FUS Proteins 0.000 claims description 8
- 101700018595 gp64 Proteins 0.000 claims description 8
- 241000382353 Pupa Species 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000003612 virological Effects 0.000 claims description 5
- 102000033180 ERVK-6 Human genes 0.000 claims description 4
- 101710038044 ERVK-6 Proteins 0.000 claims description 4
- 101710027967 ERVW-1 Proteins 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 101710023234 Segment 5 Proteins 0.000 claims description 4
- 101700028070 VPX Proteins 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 3
- BLEMLGBVQSNDOD-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CN=C2[C]1C(Cl)=C(Br)C=C2 BLEMLGBVQSNDOD-AEOCFKNESA-N 0.000 claims description 3
- 101710012186 SLC7A1 Proteins 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241001260012 Bursa Species 0.000 abstract 1
- 241000710777 Classical swine fever virus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000038129 antigens Human genes 0.000 abstract 1
- 108091007172 antigens Proteins 0.000 abstract 1
- 238000011031 large scale production Methods 0.000 abstract 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 16
- LXWYCLOUQZZDBD-LIYNQYRNSA-N CSFV Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 10
- 210000002966 Serum Anatomy 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000036039 immunity Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 5
- 101710039709 ant4 Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000614 Poison Toxicity 0.000 description 4
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 4
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 4
- 230000005591 charge neutralization Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- NPDLYUOYAGBHFB-UHFFFAOYSA-N Asparaginyl-Arginine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N NPDLYUOYAGBHFB-UHFFFAOYSA-N 0.000 description 3
- WXOFKRKAHJQKLT-UHFFFAOYSA-N Cysteinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CS WXOFKRKAHJQKLT-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- GVUVRRPYYDHHGK-UHFFFAOYSA-N Prolyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C1CCCN1 GVUVRRPYYDHHGK-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 3
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 3
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 3
- MFEVVAXTBZELLL-UHFFFAOYSA-N Tyrosyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-UHFFFAOYSA-N 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 108010037850 glycylvaline Proteins 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000000521 hyperimmunizing Effects 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000000405 serological Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- FAQVCWVVIYYWRR-WHFBIAKZSA-N (2S)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 2
- OCYROESYHWUPBP-VGMNWLOBSA-N (2S,3R)-3-methyl-2-[[(2S)-pyrrolidin-1-ium-2-carbonyl]amino]pentanoate Chemical compound CC[C@@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 OCYROESYHWUPBP-VGMNWLOBSA-N 0.000 description 2
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 2
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 2
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 2
- JQDFGZKKXBEANU-UHFFFAOYSA-N Alanyl-Cysteine Chemical compound CC(N)C(=O)NC(CS)C(O)=O JQDFGZKKXBEANU-UHFFFAOYSA-N 0.000 description 2
- XTWSWDJMIKUJDQ-RYUDHWBXSA-N Arg-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XTWSWDJMIKUJDQ-RYUDHWBXSA-N 0.000 description 2
- XNSKSTRGQIPTSE-UHFFFAOYSA-N Arginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCCNC(N)=N XNSKSTRGQIPTSE-UHFFFAOYSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 description 2
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 2
- HSPSXROIMXIJQW-BQBZGAKWSA-N Asp-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 HSPSXROIMXIJQW-BQBZGAKWSA-N 0.000 description 2
- DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 2
- VBKIFHUVGLOJKT-UHFFFAOYSA-N Asparaginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(N)=O VBKIFHUVGLOJKT-UHFFFAOYSA-N 0.000 description 2
- FKBFDTRILNZGAI-UHFFFAOYSA-N Aspartyl-Cysteine Chemical compound OC(=O)CC(N)C(=O)NC(CS)C(O)=O FKBFDTRILNZGAI-UHFFFAOYSA-N 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- RGTVXXNMOGHRAY-UHFFFAOYSA-N Cysteinyl-Arginine Chemical compound SCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RGTVXXNMOGHRAY-UHFFFAOYSA-N 0.000 description 2
- WYVKPHCYMTWUCW-UHFFFAOYSA-N Cysteinyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CS WYVKPHCYMTWUCW-UHFFFAOYSA-N 0.000 description 2
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 description 2
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 2
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 2
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 2
- 210000000087 Hemolymph Anatomy 0.000 description 2
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 2
- VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 description 2
- 101710004181 INTS2 Proteins 0.000 description 2
- CNPNWGHRMBQHBZ-ZKWXMUAHSA-N Ile-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O CNPNWGHRMBQHBZ-ZKWXMUAHSA-N 0.000 description 2
- UCGDDTHMMVWVMV-FSPLSTOPSA-N Ile-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(O)=O UCGDDTHMMVWVMV-FSPLSTOPSA-N 0.000 description 2
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 2
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 2
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- JYOAXOMPIXKMKK-UHFFFAOYSA-N Leucyl-Glutamine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CCC(N)=O JYOAXOMPIXKMKK-UHFFFAOYSA-N 0.000 description 2
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 2
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- BXNGIHFNNNSEOS-UWVGGRQHSA-N Phe-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 BXNGIHFNNNSEOS-UWVGGRQHSA-N 0.000 description 2
- HWMGTNOVUDIKRE-UWVGGRQHSA-N Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 HWMGTNOVUDIKRE-UWVGGRQHSA-N 0.000 description 2
- 241000188845 Porcine adenovirus Species 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- LDEBVRIURYMKQS-UHFFFAOYSA-N Serinyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CO LDEBVRIURYMKQS-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 2
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- STKYPAFSDFAEPH-LURJTMIESA-N gly-val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OPINTGHFESTVAX-UHFFFAOYSA-N γ-glutamyl-Arginine Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N OPINTGHFESTVAX-UHFFFAOYSA-N 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N (2R)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoic acid Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N (2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- POTCZYQVVNXUIG-BQBZGAKWSA-N (2S)-1-[2-[[(2S)-2-amino-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N (2S)-1-[2-[[(2S)-2-azaniumyl-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carboxylate Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- ZAVCJRJOQKIOJW-KKUMJFAQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]butanedioic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=CC=C1 ZAVCJRJOQKIOJW-KKUMJFAQSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N (2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N (2S)-2-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N (4S)-4-amino-5-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N (4S)-4-amino-5-[[(2S,3S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- KTGFOCFYOZQVRJ-UHFFFAOYSA-N 2-[(2-amino-3-methylpentanoyl)amino]pentanedioic acid Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-UHFFFAOYSA-N 0.000 description 1
- SNFUTDLOCQQRQD-UHFFFAOYSA-N 2-[(2-amino-4-carboxybutanoyl)amino]-3-methylpentanoic acid Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SNFUTDLOCQQRQD-UHFFFAOYSA-N 0.000 description 1
- FPTXMUIBLMGTQH-ONGXEEELSA-N 2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N 2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N 2-[[(2S)-2-[[(2S)-2-azaniumyl-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetate Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N 2-[[2-[[(2S)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PABVKUJVLNMOJP-UHFFFAOYSA-N 4-amino-5-[(1-carboxy-2-sulfanylethyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CS)C(O)=O PABVKUJVLNMOJP-UHFFFAOYSA-N 0.000 description 1
- TUTIHHSZKFBMHM-UHFFFAOYSA-N 4-amino-5-[(3-amino-1-carboxy-3-oxopropyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O TUTIHHSZKFBMHM-UHFFFAOYSA-N 0.000 description 1
- MPZWMIIOPAPAKE-UHFFFAOYSA-N 4-amino-5-[[1-carboxy-4-(diaminomethylideneamino)butyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(C(O)=O)CCCN=C(N)N MPZWMIIOPAPAKE-UHFFFAOYSA-N 0.000 description 1
- JQYMTWAYICIIQO-UHFFFAOYSA-N 4-methoxy-6-piperidin-1-ylbenzene-1,3-dicarbaldehyde Chemical compound C1=C(C=O)C(OC)=CC(N2CCCCC2)=C1C=O JQYMTWAYICIIQO-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N 8-Hydroxyquinoline Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- ROWCTNFEMKOIFQ-YUMQZZPRSA-N Arg-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N ROWCTNFEMKOIFQ-YUMQZZPRSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- QADCERNTBWTXFV-JSGCOSHPSA-N Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(O)=O)=CNC2=C1 QADCERNTBWTXFV-JSGCOSHPSA-N 0.000 description 1
- JSLGXODUIAFWCF-UHFFFAOYSA-N Arginyl-Asparagine Chemical compound NC(N)=NCCCC(N)C(=O)NC(CC(N)=O)C(O)=O JSLGXODUIAFWCF-UHFFFAOYSA-N 0.000 description 1
- IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
- FFMIYIMKQIMDPK-BQBZGAKWSA-N Asn-His Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 FFMIYIMKQIMDPK-BQBZGAKWSA-N 0.000 description 1
- GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 1
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
- MQLZLIYPFDIDMZ-UHFFFAOYSA-N Asparaginyl-Isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(N)=O MQLZLIYPFDIDMZ-UHFFFAOYSA-N 0.000 description 1
- OMSMPWHEGLNQOD-UHFFFAOYSA-N Asparaginyl-Phenylalanine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UHFFFAOYSA-N 0.000 description 1
- RGGVDKVXLBOLNS-UHFFFAOYSA-N Asparaginyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CC(N)=O)N)C(O)=O)=CNC2=C1 RGGVDKVXLBOLNS-UHFFFAOYSA-N 0.000 description 1
- VGRHZPNRCLAHQA-UHFFFAOYSA-N Aspartyl-Asparagine Chemical compound OC(=O)CC(N)C(=O)NC(CC(N)=O)C(O)=O VGRHZPNRCLAHQA-UHFFFAOYSA-N 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Aspartyl-L-proline Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- ZVDPYSVOZFINEE-UHFFFAOYSA-N Aspartyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC(O)=O ZVDPYSVOZFINEE-UHFFFAOYSA-N 0.000 description 1
- BVRPESWOSNFUCJ-LKTVYLICSA-N BNC210 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 BVRPESWOSNFUCJ-LKTVYLICSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N Bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- ZSRSLWKGWFFVCM-WDSKDSINSA-N Cys-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O ZSRSLWKGWFFVCM-WDSKDSINSA-N 0.000 description 1
- HAYVTMHUNMMXCV-UHFFFAOYSA-N Cysteinyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CS HAYVTMHUNMMXCV-UHFFFAOYSA-N 0.000 description 1
- AYKQJQVWUYEZNU-UHFFFAOYSA-N Cysteinyl-Asparagine Chemical compound SCC(N)C(=O)NC(C(O)=O)CC(N)=O AYKQJQVWUYEZNU-UHFFFAOYSA-N 0.000 description 1
- VBIIZCXWOZDIHS-UHFFFAOYSA-N Cysteinyl-Isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CS VBIIZCXWOZDIHS-UHFFFAOYSA-N 0.000 description 1
- NXTYATMDWQYLGJ-UHFFFAOYSA-N Cysteinyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CS NXTYATMDWQYLGJ-UHFFFAOYSA-N 0.000 description 1
- OELDIVRKHTYFNG-UHFFFAOYSA-N Cysteinyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)CS OELDIVRKHTYFNG-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- HTOOKGDPMXSJSY-STQMWFEESA-N His-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 HTOOKGDPMXSJSY-STQMWFEESA-N 0.000 description 1
- HZYHBDVRCBDJJV-HAFWLYHUSA-N Ile-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O HZYHBDVRCBDJJV-HAFWLYHUSA-N 0.000 description 1
- DRCKHKZYDLJYFQ-UHFFFAOYSA-N Isoleucyl-Threonine Chemical compound CCC(C)C(N)C(=O)NC(C(C)O)C(O)=O DRCKHKZYDLJYFQ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N L-tyrosyl-L-tyrosine Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- DVCSNHXRZUVYAM-BQBZGAKWSA-N Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 1
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N Leu-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
- FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 description 1
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 1
- JPNRPAJITHRXRH-UHFFFAOYSA-N Lysyl-Asparagine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC(N)=O JPNRPAJITHRXRH-UHFFFAOYSA-N 0.000 description 1
- IGRMTQMIDNDFAA-UHFFFAOYSA-N Lysyl-Histidine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 IGRMTQMIDNDFAA-UHFFFAOYSA-N 0.000 description 1
- UASDAHIAHBRZQV-YUMQZZPRSA-N Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N UASDAHIAHBRZQV-YUMQZZPRSA-N 0.000 description 1
- QTZXSYBVOSXBEJ-WDSKDSINSA-N Met-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O QTZXSYBVOSXBEJ-WDSKDSINSA-N 0.000 description 1
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 1
- IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 description 1
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 1
- PESQCPHRXOFIPX-RYUDHWBXSA-N Met-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-RYUDHWBXSA-N 0.000 description 1
- JMEWFDUAFKVAAT-UHFFFAOYSA-N Methionyl-Asparagine Chemical compound CSCCC(N)C(=O)NC(C(O)=O)CC(N)=O JMEWFDUAFKVAAT-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- JXWLMUIXUXLIJR-QWRGUYRKSA-N Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JXWLMUIXUXLIJR-QWRGUYRKSA-N 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 108050006987 Poxvirus Proteins 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- HXNYBZQLBWIADP-UHFFFAOYSA-N Prolyl-Cysteine Chemical compound OC(=O)C(CS)NC(=O)C1CCCN1 HXNYBZQLBWIADP-UHFFFAOYSA-N 0.000 description 1
- BEPSGCXDIVACBU-UHFFFAOYSA-N Prolyl-Histidine Chemical compound C1CCNC1C(=O)NC(C(=O)O)CC1=CN=CN1 BEPSGCXDIVACBU-UHFFFAOYSA-N 0.000 description 1
- 241000338310 Pseudofabraea citricarpa Species 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 229940047431 Recombinate Drugs 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 1
- UQTNIFUCMBFWEJ-UHFFFAOYSA-N Threoninyl-Asparagine Chemical compound CC(O)C(N)C(=O)NC(C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-UHFFFAOYSA-N 0.000 description 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 1
- IMMPMHKLUUZKAZ-WMZOPIPTSA-N Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 IMMPMHKLUUZKAZ-WMZOPIPTSA-N 0.000 description 1
- GRQCSEWEPIHLBI-UHFFFAOYSA-N Tryptophyl-Asparagine Chemical compound C1=CC=C2C(CC(N)C(=O)NC(CC(N)=O)C(O)=O)=CNC2=C1 GRQCSEWEPIHLBI-UHFFFAOYSA-N 0.000 description 1
- KBUBZAMBIVEFEI-UHFFFAOYSA-N Tryptophyl-Histidine Chemical compound C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 KBUBZAMBIVEFEI-UHFFFAOYSA-N 0.000 description 1
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- WPSXZFTVLIAPCN-UHFFFAOYSA-N Valyl-Cysteine Chemical compound CC(C)C(N)C(=O)NC(CS)C(O)=O WPSXZFTVLIAPCN-UHFFFAOYSA-N 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- KGNSGRRALVIRGR-UHFFFAOYSA-N gln-tyr Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 KGNSGRRALVIRGR-UHFFFAOYSA-N 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N gly pro Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine zwitterion Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002480 immunoprotection Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010082795 phenylalanyl-arginyl-arginine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- ZQFAGNFSIZZYBA-UHFFFAOYSA-N γ-glutamyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CCC(N)=O)N)C(O)=O)=CNC2=C1 ZQFAGNFSIZZYBA-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
The invention relates to a classical swine fever vaccine and a preparation method thereof and belongs to the technical field of biomedicine. According to the invention, main antigen genes E2 and E0 of the classical swine fever virus are displayed on the surface of silkworm rhabdovirus bursa by constructing a recombinant rhabdovirus and utilizing a rhabdovirus surface display technology; the recombinant rhabdovirus is produced by using silkworm pupae as a bioreactor; and the classical swine fever vaccine is produced by using the recombinant rhabdovirus as classical swine fever vaccine source. Compared with the traditional production method for the classical swine fever vaccine, the method has the characteristics of high safety, low production cost, high yield, simplicity in operation and suitability for large-scale production and has wide application prospect.
Description
Technical field
The present invention relates to a kind of swine Fever Vaccine and preparation method thereof, relate in particular to the preparation of recombinant plasmid and recombinant virus in the swine Fever Vaccine preparation, belong to the biological medicine technology field.
Background technology
(hog cholera HC) claims that again (classical swine fever CSF), is the hot transmissible disease of a kind of height contact that is caused by CSFV (CSFV) to classic swine fever, and mortality ratio is up to more than 90% to swine fever.1984 OIE (OIE) list it in category-A transmissible disease, also be one of main transmissible disease of paying close attention to of the World Food Programme and national governments.
After Hungary HutyraK-oves processed the swine fever hyper-immune serum in 1908, people used hyper-immune serum-blood poison intramuscular injection simultaneously to come immune swinery always.But because hyper-immune serum costs an arm and a leg, obtain difficulty, the blood poison has the danger of the poison that looses in addition, thus the various countries scholar afterwards 60 in the period of develop many inactivated vaccines in succession, wherein Superlysoform and Viola crystallina inactivated vaccine once were widely used.Though inactivated vaccine safety, preservation period is short.
Nineteen fifty-five, people such as Zhou Taichong successfully prepare the rabbitization low virulent strain with CSFV crossdrift virulent strain after the rabbit body goes down to posterity for 214 times.Continue to go down to posterity 480 times, become commercial standard vaccine strain.Be named as Chinese vaccine strain (C-strain) or hog cholera lapinised virus (HCLV) strain afterwards, a lot of commercial vaccine strains are all derived by it.Be widely used in world many countries since nineteen fifty-seven, be most popular in the world at present a little less than malicious seedling, played keying action to control CSF is popular.Compare other commercial vaccine, its security is higher, and bacterium continues to exist in the pig body to be no more than for 3 weeks, and can not cause the morbidity of piglet and farrowing sow; Immune effect is better, and immunity once just can produce protection completely, and guard time reaches 1 year even be lifelong.Although conventional less toxic vaccine is safe and effective; But there is immune antibody and infects the undistinguishable problem of antibody; Can not detect a wild virus infection in the immune swinery through serological method, this anti-system for swine fever is very unfavorable with purification, also just because of this reason; Take the pig of hog cholera immune policy country and the outlet of goods thereof to receive strict restriction, this just makes exploitation to become the task of top priority with the new generation vaccine that serological method is distinguished immune swine and infected pigs.
Subunit vaccine is one type of ability is distinguished immune animal and infection animal easily through serological method a vaccine.At present existing 2 kinds of subunit vaccines have obtained registration in European Union, and these 2 kinds of vaccines all are that CSFV E2 albumen with baculovirus expression is as immunogen.But also there are some defectives in this vaccine, and test shows that the E2 protein subunit vaccine could produce the protection to wild virus infection behind immune 14d; Simultaneously; If there is low-level maternal antibody to exist during immunity in the body; At least want immunity just can induce clinical protection twice, even so, most of pigs that produced clinical protection still have heating, oligoleukocythemia and viremia when attacking poison situation occurs.In addition, can the E2 protein subunit vaccine prevent horizontal transmission and vertical transmission also to remain to be confirmed.
The live recombinant vectors vaccine is the marker vaccine that begins one's study at first, and live vector vaccine can cause humoral immunization and cellular immunization, and can duplicate in vivo, can induce long-term and immunoprotection efficiently.The virus vector that is used for the swine fever marker vaccine has poxvirus, pseudorabies virus (PRV), porcine adenovirus (PAV) etc.But they all have obvious defects: vaccinia virus recombinant possibly have the potential infectivity to the people who did not inoculate bovine vaccine; Vaccinia virus recombinant propagates in the environment and possibly recombinate with the wild-type vaccinia virus, virulence occurs and returns strong phenomenon; Vaccinia virus is lower to the infectivity of pig, must inject the vaccinia virus recombinant of high dosage and just can induce effective protection; Be not suitable for the popular area of pseudoabies based on the PRV carrier bacterin, because PRV antibody has certain influence for immunity and serology detection; Though and rPAV-E2 and rPRV-E2 are efficient and safety, do not obtain concrete vaccine test or field experiment and confirm.
Dna vaccination possesses a lot of advantages; Develop very fast; But also there is the potential potential safety hazard; Whether can be incorporated in the host genome, whether can cause that problem such as immunological tolerance it be unclear that like DNA, and have certain potential safety hazard, the dna vaccination immune efficacy still remains further to be improved in addition.
Based on above various situation, studying novel, effective swine Fever Vaccine has been investigator's striving direction, and E2, E0 albumen be the major antigen site of CSFV, is the main target spot of swine Fever Vaccine development.
The baculovirus surface display system is a kind of new eucaryon display systems that grew up in recent years; Can remedy the deficiency of protokaryon display systems; And the advantage of maintenance surface display system; Promptly be convenient to the purifying of foreign protein through the recombinant baculovirus particle of screening expression differential protein; Can be used to show to need the just active complicated eukaryotic protein of the function of appeal of posttranslational modifications such as glycosylation, disulfide linkage isomerizing, have broad application prospects at aspects such as the screening of high-affinity antibody and polypeptide drugs, proteantigen epitope analysis.
Summary of the invention
In view of this, the object of the present invention is to provide a kind of swine Fever Vaccine that overcomes above-mentioned defective.The present invention is through making up a kind of recombinant silkworm baculovirus; And use baculovirus surface display technology that major antigen gene E2, the E0 fusion of CSFV are illustrated in silkworm baculovirus cyst membrane surface; Produce recombinant baculovirus with silkworm pupa as bio-reactor; And produce as swine Fever Vaccine is former with this recombinant baculovirus, have that security is good, production cost is low, output is high, easy handling, be applicable to the characteristics of scale operation than traditional swine Fever Vaccine production.
For achieving the above object, the technical scheme that the present invention adopts is following:
A kind of silkworm with recombinant baculovirus Bmgp64-E2-2A-E0; This virus is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on December 15th, 2011; It abbreviates CGMCC (address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City as; Institute of Microorganism, Academia Sinica, postcode 100101) preservation, classification called after Bombyx mori nuclear polyhydrosis virus (
Bombyx mori nucleopolyhedrovirus), deposit number is CGMCC No.5604.
The preparation method of above-mentioned silkworm with recombinant baculovirus may further comprise the steps:
(a) method by pcr amplification obtains baculovirus envelope protein gp64 signal peptide gene sequence SP and baculovirus envelope protein gp64 membrane-spanning domain gene order TM, through
BamH I/
EcoR I with
XhoI/
HindThe III double digestion inserts pFastBacI carrier MCS upstream and downstream two ends, makes up surface display system transfer vector pFastBacI-gp64;
(b) adopting the pvL1393-E2-2A-E0 recombinant plasmid is template, is that primer carries out pcr amplification with SEQ ID:NO.6 and SEQ ID:NO.7, gene fusion construct E2-2A-E0;
(c) on fusion gene E2-2A-E0 double digestion product cloning to step (a) the gained surface display system transfer vector pFastBacI-gp64 with step (b) gained, and screening positive clone, obtain to shift recombinant plasmid pFastBacI-gp64-E2-2A-E0;
(d) step (c) gained is shifted recombinant plasmid pFastBacI-gp64-E2-2A-E0 transformed into escherichia coli DH10Bac competent cell; Carry out the screening of blue hickie on the LB culture plate of kantlex, qingfengmeisu qiong, tsiklomitsin, X-gal and IPTG containing; Picking hickie behind the lucifuge cultivation 40-48h, bacterium liquid dilution 10 behind the cultivation 16-20h
6Again coated plate is done screening, after picking hickie to LB substratum shakes bacterium cultivation 16-20h, with Virahol extracting recombinant baculovirus genome, and is PCR with the M13 universal primer and identifies;
(e) get step (d) the successful recombinant virus genomes of identifying through liposome mediated-method transfection silkworm BmN cell; The morbidity back obtains zero for viral suspension 0-4 ℃ preservation; Extract viral genome and carry out the PCR evaluation, obtain said silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 with the M13 universal primer.
Above-mentioned recombinant baculovirus Bmgp64-E2-2A-E0 expressed proteins, its aminoacid sequence is shown in SEQ ID:NO.11.
Above-mentioned proteic preparation method may further comprise the steps:
(a) above-mentioned recombinant baculovirus Bmgp64-E2-2A-E0 infected silkworm BmN cell is carried out virus amplification;
(b) with stab inoculation inoculation silkworm five-age larva, pupa;
(c) collect the above-mentioned albumen of expressing.
The present invention further provides above-mentioned silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 application in the swine Fever Vaccine preparation.
The present invention also provides the application of above-mentioned albumen in the swine Fever Vaccine preparation.
The present invention has following beneficial effect:
The present invention utilizes silkworm pupa, five-age larva to be bio-reactor; Efficiently express CSFV major antigen albumen E2 and E0; Through with baculovirus gp64 proteic N end signal peptide and C end span film district and E2-2A-E0 gene fusion; Make CSFV major antigen recombination fusion protein be showed in baculovirus cyst membrane surface and form the pseudo-virus of baculovirus that has the exogenous virus major antigen; This puppet virus has the immunogenicity of exogenous virus, can be used as the recombination engineered vaccine, and baculovirus expression vector system belongs to eukaryotic expression system; Having the processing rhetorical function after the translation, is that the foreign protein of expressing has and more approaches natural biological activity.Because albumen is nontoxic to people and animals in the silkworm pupa, so the recombinant vaccine that the present invention is bio-reactor with the silkworm chrysalis to produce is little to the spinoff that people and animals produce, and is applicable to scale operation, production cost is low.In addition, the present invention's development of using silkworm baculovirus surface display technological expression CSFV recombination fusion protein E2-2A-E0 to be used for swine Fever Vaccine also still belongs to the first.
Description of drawings
Fig. 1 is the collection of illustrative plates of the baculovirus surface display system transfer vector pFastBacI-gp64 that makes up among the present invention;
Fig. 2 is the collection of illustrative plates synoptic diagram of the recombinant transfer plasmid pFastBacI-gp64-E2-2A-E0 that makes up of the present invention;
Fig. 3 is the mode chart of the recombinant baculovirus Bmgp64-E2-2A-E0 that makes up of the present invention.
Embodiment
Be noted that following specifying all is exemplary, being intended to provides further invention to the present invention.Except as otherwise noted, all Science and Technology terms of using of this paper have with the present invention under the identical meanings of person skilled common sense.
Specify particular content of the present invention below in conjunction with embodiment.
Embodiment 1: the acquisition of fusion gene E2-2A-E0
The sequence (gene accession number: E0 is EF015292.1, and E2 is DQ907718.1) that goes up CSFV E2, E0 gene according to NCBI designs the upstream primer SEQ ID:NO.6 of raq gene and the downstream primer SEQ ID:NO.7 of E0 gene, and upstream primer is introduced
EcoRThe I restriction enzyme site, downstream primer is introduced
XhoThe I restriction enzyme site is a template with the pvL1393-E2-2A-E0 recombinant plasmid that the Zhang Zhi of Chinese Academy of Agricultural Sciences virtue teacher gives, and carries out pcr amplification, obtains fusion gene E2-2A-E0, its nucleotide sequence and aminoacid sequence such as SEQ ID:NO.10.Specific procedure and reaction system are following:
Response procedures:
Reaction system:
10×PCR Buffer 5 μl
25mM MgCl
2 4 μl
2.5mM dNTPs 4 μl
SEQ ID: NO.6 1 μl
SEQ ID: NO.7 1 μl
Template 1 μ l
KOD Plus DNA polysaccharase (TOYOBO company) 1 μ l
Add aseptic ddH
2O to 50 μ l
The PCR product is used
EcoR I,
XhoAfter I (all available from Invitrogen company) carried out double digestion, rubber tapping was reclaimed for future use.
Embodiment 2: the structure of baculovirus surface display system transfer vector pFastBacI-gp64
(the gene number of landing is: L33180.1) to go up the baculovirus gp64 gene order that obtains according to NCBI; Design primer SEQ ID:NO.2, SEQ ID:NO.3 go out its signal peptide (SP) sequence through overlap extension pcr (SOE-PCR) specific amplified; With SEQ ID:NO.4, SEQ ID:NO.5 is primer; The wild baculovirus genome that extracts goes out to stride diaphragm area (TM) sequence for the template specific amplified; Like SEQ ID:NO.9, and be that stencil design is identified upstream primer SEQ ID:NO.1 with the SP sequence of obtaining on the NCBI, it is following that each goes on foot concrete response procedures:
(1) the SP sequence is synthetic:
Response procedures:
Reaction system:
10×PCR Buffer 5 μl
25mM MgCl
2 4 μl
2.5mM dNTPs 4 μl
SEQ ID: NO.2 1 μl
SEQ ID: NO.3 1 μl
KOD Plus DNA polysaccharase (TOYOBO company) 1 μ l
Add aseptic ddH
2O to 50 μ l
The PCR product is used
BamHI,
EcoAfter R I (all available from Fermentas company) carried out double digestion, rubber tapping was reclaimed for future use.
(2) the TM sequence is synthetic:
Response procedures:
Reaction system:
10×PCR Buffer 5 μl
25mM MgCl
2 4 μl
2.5mM dNTPs 4 μl
SEQ ID: NO.4 1 μl
SEQ ID: NO.5 1 μl
Genomic templates 1 μ l
KOD Plus DNA polysaccharase (TOYOBO company) 1 μ l
Add aseptic ddH
2O to 50 μ l
The PCR product is used
XhoI,
HindAfter III carried out double digestion, rubber tapping was reclaimed for future use.
With the PCR product behind (1), (2) the two groups of double digestions; Be cloned into respectively successively on the unloaded plasmid of pFastBacI (available from Invitrogen company); Transformed into escherichia coli TG1 competent cell (available from Invitrogen company); Picking list bacterium colony utilizes above-mentioned PCR primers designed SEQ ID:NO.1 and SEQ ID:NO.5 to carry out PCR and identifies, and carries out double digestion and identify with order-checking; The plasmid that positive colony is got in screening is baculovirus surface display system transfer vector pFastBacI-gp64, and is as shown in Figure 1.
Embodiment 3: the structure of baculovirus surface display system transferring plasmid pFastBacI-gp64-E2-2A-E0
To transfer vector pFastBacI-gp64, screening positive clone is baculovirus surface display system transferring plasmid pFastBacI-gp64-E2-2A-E0, and is as shown in Figure 2 with the fusion gene E2-2A-E0 double digestion product cloning that reclaims among the embodiment 1.
Embodiment 4: recombinant baculovirus Bmgp64-E2-2A-E0 obtaining and identifying
With the recombinant transfer plasmid pFastBacI-gp64-E2-2A-E0 transformed into escherichia coli DH10Bac competent cell (available from Invitrogen company) that is obtained among the embodiment 3; On the LB solid culture plate (ordinary method preparation) that contains kantlex, qingfengmeisu qiong, tsiklomitsin, X-gal and IPTG (sec.-propyl-β-D-sulfo-galactopyranoside), carry out blue hickie screening available from Bio Basic Inc company; Picking list bacterium colony hickie behind the lucifuge cultivation 48h, bacterium liquid dilution 10 behind the cultivation 16h
6Again coated plate is done screening, after picking hickie to LB substratum shakes bacterium cultivation 16h, with Virahol extracting recombinant baculovirus genome in super clean bench, identifies with the M13 universal primer PCR whether swivel base is successful.
M13 upstream primer: 5 '-GTTTTCCCAGTCACGAC-3 '
M13 downstream primer: 5 '-CAGGAAACAGCTATGAC-3 '
With identifying the method for successful recombinant baculovirus genome with reference to the lipofectamine Cellfectin of Invitrogen company II Reagent specification sheets; Through liposome mediated-method transfection silkworm BmN cell (is first generation cross-fertilize seed cyanines pine * bright moons; Biochemical institute gives by Shanghai); Treat this silkworm BmN cell morbidity (microscopically observations) back collection first-generation recombinant virus suspension and in 4 ℃ of preservations; Extract viral genome with Viral DNA Kit (200) (available from OMEGA company), carry out PCR with the M13 universal primer then and identify.Gained is identified successful recombinant baculovirus called after Bmgp64-E2-2A-E0, as shown in Figure 3.
Embodiment 5: expression (amplification) and the evaluation of recombinant baculovirus Bmgp64-E2-2A-E0 in silkworm BmN cell
In the dosage infected silkworm BmN cell log vegetative period silkworm BmN cell of the recombinant baculovirus Bmgp64-E2-2A-E0 that obtains among the embodiment 4 with MOI=0.1pfu/cell; In containing 1 * Sf-900 II SFM substratum (available from Invitrogen company) of 10% foetal calf serum, cultivate 3～4 d for 27 ℃, collect culture supernatant; 4 ℃, it is frozen in-70 ℃ that centrifugal 10 min of 500 * g, supernatant store in 4 ℃ or packing.Recombinant baculovirus after the amplification with MOI=10 pfu/cell dosage infected silkworm BmN cell (be first generation cross-fertilize seed cyanines pine * bright moons, biochemical institute gives by Shanghai), is cultivated 72 h at 27 ℃, 4 ℃, the centrifugal 10min collecting cell deposition of 2000g; This cell precipitation is resuspended with the PBS washing of pH 7.4, and sample mixes with 2 * SDS sample-loading buffer respectively, 60 ℃ of heating 30 min; Carry out the SDS-PAGE protein electrophoresis; Western blotting analyzes, and the result shows that fusion rotein E2-2A-E0 is successful expression in silkworm BmN cell.
Embodiment 6: expression and the evaluation of recombinant baculovirus Bmgp64-E2-2A-E0 in silkworm five-age larva and silkworm chrysalis
(is first generation cross-fertilize seed cyanines pine * bright moons with the silkworm five-age larva of the recombinant baculovirus Bmgp64-E2-2A-E0 after embodiment 5 amplification after with the dosage belly joint second from the bottom place percutaneous puncture-inoculation molting of MOI=10 pfu/cell with the silkworm chrysalis of pupating two days; Zhongqi Biological Pharmaceutical Co., Ltd., Zhejiang); Typical virus infection symptom appears in the 5th day most of larva and silkworm chrysalis; Cut the larva abdominal foot and collect the silkworm hemolymph; Add 0.5% (w/v) inhibitor 8-hydroxy-quinoline, the centrifugal 10min of 12000rpm gets supernatant; With silkworm chrysalis-80 ℃ storage.The homogenate of getting cleer and peaceful morbidity silkworm chrysalis on the silkworm hemolymph of 12000rpm after centrifugal adds isopyknic 2 * protein sample-loading buffer (100Mm Tris-HCl respectively; 4% SDS; 0.1% tetrabromophenol sulfonphthalein, 10% glycerine), 60 ℃ of heating 30min; Get 20 μ l and carry out the SDS-PAGE protein electrophoresis, and carry out Western blotting and analyze.The result shows that fusion rotein E2-2A-E0 has obtained successful expression in silkworm larva and silkworm pupa.
Embodiment 7: the acquisition of novel swine Fever Vaccine
(1) separation and purification recombinant virus Bmgp64-E2-2A-E0 from silkworm chrysalis:
A. get the silkworm chrysalis sample that 300g infects through Bmgp64-E2-2A-E0, after thawing under 4 ℃, with 4 ℃ of ddH that place 1 h
2O 300ml mixes, and places refiner, and homogenate 2min places 2min on ice, repeats 9 times;
B. homogenate is added in the 1L Centrifuge Cup, trim, the centrifugal 60min of 6000rpm gets supernatant, carefully discards grease;
C. the 6000rpm centrifuged supernatant is poured in another 1L Centrifuge Cup, trim, the centrifugal 60min of 6000rpm gets supernatant, abandons grease;
D. repeat c once;
E. 6000rpm centrifugal supernatant is poured the 50ml centrifuge tube into, trim, and the centrifugal 30min of 12000rpm gets supernatant, abandons grease (it is inferior to repeat this step 3);
F. get the supernatant 300ml of 12000rpm after centrifugal; Carry out ultrafiltration with 300kD hollow-fibre membrane film bag ultrafiltration system 4 ℃ (available from Sartorius companies); Be appearance ultrafiltration on the volume ratio of 1:1 according to supernatant and PBS, so repeat final trapped fluid 100ml 10 times; Clean the film bag with 200ml PBS again, and merge with the liquid that dams;
G. the sample after the ultrafiltration is sub-packed in the ultra in pipe of sterilization, balance, the centrifugal 40min of 40000rpm ultra-high speed on super clean bench;
H. 40000rpm centrifugal after, get all supernatants, and the resuspended liquid of deposition (all depositions are resuspended with 50ml PBS) carries out band centrifugation respectively, last kind in proper order as follows: PBS 250ml; Sample 300ml, 30% sucrose solution 400ml, 55% sucrose solution is full of, and sample introduction adds upper cap after finishing; Close door, the open vacuum pump begins centrifugal, and centrifugal end back is with following kind of 56% sucrose solution; With the monitoring of nucleic acid-protein detector, collect and flow out sample, altogether 150mL;
I. sample leaves standstill deactivation 24h for 37 ℃ with thousand/dicarbaldehyde behind the band centrifugation;
J. ultrafiltration desugar: sample to 50mL, is diluted to 100mL with sterilized water with the ultrafiltration of 300kD hollow-fibre membrane film bag again after the deactivation, and ultrafiltration is to 50mL again; So repeat 10 times, finally holding back volume is 50mL, uses the aseptic moisture of 300mL 3 times again; Each 100mL; The circulation flushing ultrafiltration system finally is concentrated into 50mL, merges the two times of ultrafiltration liquid that dams;
(2) freeze-drying: sample after the ultrafiltration desugar, active with the indirect elisa method detection of biological, activated sample carries out packing, in-40 ℃ of lyophilizes;
(3) preserve and detect:
Novel swine Fever Vaccine lyophilized powder is processed in aseptic subpackaged warp-40 ℃ lyophilize.Simultaneously, identify the biological activity of fusion rotein E2-2A-E0 in the lyophilized powder again with ELISA.The 12%SDS-PAGE electrophoresis, test sample has the expression of target protein at the 95kD place.
(4) the Balb/c mouse in 4 ages in week of recombinant virus particle immunity after getting purifying and identifying prepares polyclonal antibody, does serum neutralization test, and neutralization is tired and can be reached 1:32, shows to have good immunogenicity.The serum neutralization test step is following:
The Balb/c mouse polyclonal antibody of preparation is handled 30 min in 56 ℃ of water-baths, use the serial dilution of serum-free Sf-900TMSFM (1X) substratum (available from Invitrogen company) difference multiple proportions then to 2-8;
Getting the different dilution serum with equal volume of recombinant baculovirus Bmgp64-E2-2A-E0 suspension that 50 μ L prepare in advance mixes; Hatch 1h for 37 ℃; Balb/c mice serum test group with recombinant baculovirus Bmgp64-E2-2A-E0 immunity; With the Balb/c mice serum negative control group of PBS immunity, carry out in the serum and experiment;
Get the good silkworm BmN cell of growth conditions, diluting cells density to 1 * 105/mL, 500 μ L/ holes add in 24 orifice plates;
With 100 μ L/ holes inoculation BmN cell, different extent of dilution serum are done three repetitions, 27 ℃ of cultivations in the cell culture incubator with virus-serum mixture;
Observation of cell pathology situation, the calculating antibody neutralization is tired.
The above is merely preferred embodiment of the present invention, is not the present invention is done any pro forma restriction; Though the present invention discloses as above with preferred embodiment; Yet be not that any those of ordinary skill in the art is in the scope that does not break away from spirit of the present invention in order to qualification the present invention; Any modification of being done, equivalence variation and modification etc. all still belong within protection scope of the present invention.
SEQUENCE LISTING
< 110>Tianjin Yaoyu Biotechnology Co., Ltd.
< 120>a kind of swine Fever Vaccine and preparation method thereof
<130> 111665-I-CP-TJYU
<160> 11
<170> PatentIn version 3.5
<210> 1
<211> 25
<212> DNA
< 213>primer
<400> 1
ccgggatcca tggtaggcgc tattg 25
<210> 2
<211> 49
<212> DNA
< 213>primer
<400> 2
cgcggatcca tggtaggcgc tattgtttta tacgtgcttt tggcggcgg 49
<210> 3
<211> 50
<212> DNA
< 213>primer
<400> 3
cctttgaatt ccgccgcaaa ggcagaatgc gccgccgcca aaagcacgta 50
<210> 4
<211> 25
<212> DNA
< 213>primer
<400> 4
ccgctcgaga tggctgaagg cgaat 25
<210> 5
<211> 26
<212> DNA
< 213>primer
<400> 5
cccaagcttt taatattgtc tactat 26
<210> 6
<211> 25
<212> DNA
< 213>primer
<400> 6
ccggaattca tgcggctagc ctgta 25
<210> 7
<211> 25
<212> DNA
< 213>primer
<400> 7
ccgctcgagg gcataagcgc caaac 25
<210> 8
<211> 60
<212> DNA
< 213>gp64 signal peptide
<400> 8
atggtaggcg ctattgtttt atacgtgctt ttggcggcgg cgcattctgc ctttgcggcg 60
<210> 9
<211> 132
<212> DNA
< 213>gp64 strides the film district
<400> 9
atggctgaag gcgaattggc cgccaaattg acttcgttca tgtttggtca tgtagccact 60
tttgtaattg tatttattgt aattttattt ttgtactgta tggttagaaa ccgtaatagt 120
agacaatatt aa 132
<210> 10
<211> 1764
<212> DNA
< 213>E2-2A-E0 nucleotide sequence
<400> 10
atgcggctag cctgtaagga agattacagg tacgcaatat cgtcaaccga tgagataggg 60
ctacttgggg ccggaggtct caccaccacc tggaaggaat ataaccacga tttgcaactg 120
aatggcggga ccgtcaaggc cagttgcgtg gcaggttcct ttaaagtcac agcacttaat 180
gtggtcagta ggaggtattt ggcgtcactg cataagaagg ctttacccac ttccgtgaca 240
ttcgagctcc tgttcgacgg gaccaaccca tcaactgagg aaatgggaga tgacttcagg 300
tccgggctgt gcccgtttga tacgagtcct gttgttgagg gaaagtacaa tacgaccttg 360
ttgaacggta gtgccttcta tcttgtctgc ccaatagggt ggacgggtgt catagagtgc 420
acagcagtga gcccaacaac tctgaggaca gaagtggtaa agaccttcag gagagacaag 480
ccctttccgc acagaatgga ttgtgtgacc accacagtgg aaaatgaaga tttattctat 540
tgtaagttgg ggggcaactg ggcatgtgtg aaaggcgagc cagcggtcta cacaaggggg 600
gtagtagaac aacgtagatg gtgtggcttc gacttcgatg ggcctgacgg actcccgcat 660
taccccatag gtaagtgcat tttggcaaat gagacaggtt acagaatagt agattcaacg 720
gactgtaaca gagatggcgt cgtaatcagc acagagggga gtcatgagtg cttgatcggt 780
aacacgactg tcaaggtgca tgcatcagat gaaagactgg gccctatgcc atgcagacct 840
aaagagattg tctctagtgc tggtcctgta atgaaaacct cctgtacatt caactacaca 900
aaaactttga agaacaggta ctatgagccc agggacagct acttccagca atatatgctt 960
aagggtgagt atcagtattg gtttgacctg gatgcgactg accaccactc agattacttc 1020
gcagaattta actttgatct tttgaagtta gcaggagacg ttgagtccaa ccccggaccc 1080
atggaaaata taactcaatg gaacctgagt gacaacggca ctaatggtat ccagcatgct 1140
atgtacttta gaggggttaa cagaagcttg catgggatct ggccggggaa aatatgcaaa 1200
ggagtcccaa cccacctggc cacagacgtg gagctgaaag aaatacaggg aatgatggat 1260
gctagcgagg ggacaaacta tacgtgctgt aagttacaga gacatgaatg gaacaaacat 1320
ggatggtgta actggcacaa tatagacccc tggatacagc tgatgaatag aacccaagca 1380
gacttggcag aaggccctcc ggtcaaggag tgcgctgtga cttgcaggta cgataaagat 1440
gctgacatca acgtggtcac ccaggctaga aacaggccaa caaccctgac cggctgcaag 1500
aaagggaaaa atttttcttt tgcgggtaca gttatagaga gcccatgtaa tttcaatgtt 1560
tccgtggagg ataccttgta tggggatcat gagtgcggca gtttactcca ggacgcagct 1620
ctgtacctag tagatggaat gaccgacact atagagaatg ccagacaggg agcagcgagg 1680
gtgacatctt ggctcgggag gcaactcagc actgctggga agaggttgga gggtagaagc 1740
aaaacctggt ttggcgctta tgcc 1764
<210> 11
<211> 540
<212> PRT
< 213>recombination fusion protein
<400> 11
Met Arg Leu Ala Cys Lys Glu Asp Tyr Arg Tyr Ala Ile Ser Ser Thr
1 5 10 15
Asp Glu Ile Gly Leu Leu Gly Ala Gly Gly Leu Thr Thr Thr Trp Lys
20 25 30
Glu Tyr Asn His Asp Leu Gln Leu Asn Gly Gly Thr Val Lys Ala Ser
35 40 45
Cys Val Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val Ser Arg
50 55 60
Arg Tyr Leu Ala Ser Leu His Lys Lys Ala Leu Pro Thr Ser Val Thr
65 70 75 80
Phe Glu Leu Leu Phe Asp Gly Thr Asn Pro Ser Thr Glu Glu Met Gly
85 90 95
Asp Asp Phe Arg Ser Gly Leu Cys Pro Phe Asp Thr Ser Pro Val Val
100 105 110
Glu Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe Tyr Leu
115 120 125
Val Cys Pro Ile Gly Trp Thr Gly Val Ile Glu Cys Thr Ala Val Ser
130 135 140
Pro Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Arg Arg Asp Lys
145 150 155 160
Pro Phe Pro His Arg Met Asp Cys Val Thr Thr Thr Val Glu Asn Glu
165 170 175
Asp Leu Phe Tyr Cys Lys Leu Gly Gly Asn Trp Ala Cys Val Lys Gly
180 185 190
Glu Pro Ala Val Tyr Thr Arg Gly Val Val Glu Gln Arg Arg Trp Cys
195 200 205
Gly Phe Asp Phe Asp Gly Pro Asp Gly Leu Pro His Tyr Pro Ile Gly
210 215 220
Lys Cys Ile Leu Ala Asn Glu Thr Gly Tyr Arg Ile Val Asp Ser Thr
225 230 235 240
Asp Cys Asn Arg Asp Gly Val Val Ile Ser Thr Glu Gly Ser His Glu
245 250 255
Cys Leu Ile Gly Asn Thr Thr Val Lys Val His Ala Ser Asp Glu Arg
260 265 270
Leu Gly Pro Met Pro Cys Arg Pro Lys Glu Ile Val Ser Ser Ala Gly
275 280 285
Pro Val Met Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr Leu Lys
290 295 300
Asn Arg Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gln Gln Tyr Met Leu
305 310 315 320
Lys Gly Glu Tyr Gln Tyr Trp Phe Asp Leu Asp Ala Thr Asp His His
325 330 335
Ser Asp Tyr Phe Ala Glu Phe Asn Phe Asp Leu Leu Lys Leu Ala Gly
340 345 350
Asp Val Glu Ser Asn Pro Gly Pro Met Glu Asn Ile Thr Gln Trp Asn
355 360 365
Leu Ser Asp Asn Gly Thr Asn Gly Ile Gln His Ala Met Tyr Phe Arg
370 375 380
Gly Val Asn Arg Ser Leu His Gly Ile Trp Pro Gly Lys Ile Cys Lys
385 390 395 400
Gly Val Pro Thr His Leu Ala Thr Asp Val Glu Leu Lys Glu Ile Gln
405 410 415
Gly Met Met Asp Ala Ser Glu Gly Thr Asn Tyr Thr Cys Cys Lys Leu
420 425 430
Gln Arg His Glu Trp Asn Lys His Gly Trp Cys Asn Trp His Asn Ile
435 440 445
Asp Pro Trp Ile Gln Leu Met Asn Arg Thr Gln Ala Asp Leu Ala Glu
450 455 460
Gly Pro Pro Val Lys Glu Cys Ala Val Thr Cys Arg Tyr Asp Lys Asp
465 470 475 480
Ala Asp Ile Asn Val Val Thr Gln Ala Arg Asn Arg Pro Thr Thr Leu
485 490 495
Thr Gly Cys Lys Lys Gly Lys Asn Phe Ser Phe Ala Gly Thr Val Ile
500 505 510
Glu Ser Pro Cys Asn Phe Asn Val Ser Val Glu Asp Thr Leu Tyr Gly
515 520 525
Asp His Glu Cys Gly Ser Leu Leu Gln Asp Ala Ala
530 535 540
Claims (6)
1. silkworm with recombinant baculovirus Bmgp64-E2-2A-E0, this virus is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center, and deposit number is CGMCC No.5604.
2. the preparation method of the said silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 of claim 1 is characterized in that, said method comprising the steps of:
(a) method by pcr amplification obtains baculovirus envelope protein gp64 signal peptide gene sequence SP and baculovirus envelope protein gp64 membrane-spanning domain gene order TM, through
BamH I/
EcoR I with
XhoI/
HindThe III double digestion inserts pFastBacI carrier MCS upstream and downstream two ends, makes up surface display system transfer vector pFastBacI-gp64;
(b) adopting the pvL1393-E2-2A-E0 recombinant plasmid is template, is that primer carries out pcr amplification with SEQ ID:NO.6 and SEQ ID:NO.7, gene fusion construct E2-2A-E0;
(c) on fusion gene E2-2A-E0 double digestion product cloning to step (a) the gained surface display system transfer vector pFastBacI-gp64 with step (b) gained, and screening positive clone, obtain to shift recombinant plasmid pFastBacI-gp64-E2-2A-E0;
(d) step (c) gained is shifted recombinant plasmid pFastBacI-gp64-E2-2A-E0 transformed into escherichia coli DH10Bac competent cell; Carry out the screening of blue hickie on the LB culture plate of kantlex, qingfengmeisu qiong, tsiklomitsin, X-gal and IPTG containing; Picking hickie behind the lucifuge cultivation 40-48h, bacterium liquid dilution 10 behind the cultivation 16-20h
6Again coated plate is done screening, after picking hickie to LB substratum shakes bacterium cultivation 16-20h, with Virahol extracting recombinant baculovirus genome, and is PCR with the M13 universal primer and identifies;
(e) get step (d) the successful recombinant virus genomes of identifying through liposome mediated-method transfection silkworm BmN cell; The morbidity back obtains zero for viral suspension 0-4 ℃ preservation; Extract viral genome and carry out the PCR evaluation, obtain said silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 with the M13 universal primer.
3. the said silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 of a claim 1 fusion rotein of expressing, its aminoacid sequence is shown in SEQ ID:NO.11.
4. the said proteic preparation method of claim 3 is characterized in that, said method comprising the steps of:
(a) the described recombinant baculovirus Bmgp64-E2-2A-E0 of claim 3 infected silkworm BmN cell is carried out virus amplification;
(b) with stab inoculation inoculation silkworm five-age larva, pupa;
(c) collect the right 3 said albumen of expressing.
5. the application of the said silkworm with recombinant baculovirus Bmgp64-E2-2A-E0 of claim 1 in the swine Fever Vaccine preparation.
6. the application of the said albumen of claim 3 in the swine Fever Vaccine preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100056192A CN102559614A (en) | 2012-01-10 | 2012-01-10 | Classical swine fever vaccine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100056192A CN102559614A (en) | 2012-01-10 | 2012-01-10 | Classical swine fever vaccine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102559614A true CN102559614A (en) | 2012-07-11 |
Family
ID=46406223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100056192A Pending CN102559614A (en) | 2012-01-10 | 2012-01-10 | Classical swine fever vaccine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102559614A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014032456A1 (en) * | 2012-09-03 | 2014-03-06 | 天津耀宇生物技术有限公司 | Double-tagging silkworm recombinant baculovirus, and preparation method and use thereof |
| CN105002196A (en) * | 2015-08-01 | 2015-10-28 | 吉林农业大学 | Swine fever recombined vaccine |
| CN105527442A (en) * | 2014-09-30 | 2016-04-27 | 洛阳普莱柯万泰生物技术有限公司 | CSFV antibody detection system and preparation method thereof |
-
2012
- 2012-01-10 CN CN2012100056192A patent/CN102559614A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014032456A1 (en) * | 2012-09-03 | 2014-03-06 | 天津耀宇生物技术有限公司 | Double-tagging silkworm recombinant baculovirus, and preparation method and use thereof |
| CN105527442A (en) * | 2014-09-30 | 2016-04-27 | 洛阳普莱柯万泰生物技术有限公司 | CSFV antibody detection system and preparation method thereof |
| CN105002196A (en) * | 2015-08-01 | 2015-10-28 | 吉林农业大学 | Swine fever recombined vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585625B (en) | A kind of porcine epizootic diarrhea recombinant baculovirus genetic engineering subunit vaccine and preparation method thereof and application | |
| CN104248762B (en) | A kind of pig epidemic diarrhea vaccine combination and its preparation method and application | |
| CN104178505B (en) | A kind of expression E 2 gene of Classical Swine Fever recombinant virus and preparation method and application | |
| CN102296089B (en) | Method for efficiently preparing porcine circovirus 2 type empty capsid | |
| CN102382845B (en) | Method for producing porcine parvovirus antigen and its product | |
| CN103255171B (en) | Recombinant virus-like particles of porcine circovirus 2 type codon optimized OFRF2 gene | |
| CN107841507A (en) | A kind of porcine circovirus 2 type Cap cell-penetrating peptides antigen-4 fusion protein gene of high efficient expression and its application | |
| CN109880838A (en) | A kind of recombinant virus and its preparation method and application of the O-shaped foot-and-mouth disease virus multi-epitope gene of secreting, expressing pig | |
| CN109182380A (en) | The preparation method and application of the swine fever E2 subunit vaccine of baculovirus expression | |
| CN110423269A (en) | A kind of 2 type Cap protein of recombinant porcine circovirus and its application of Dominant Epitopes of connecting | |
| CN103789274B (en) | A kind of rabbit hemorrhagic disease virus recombinant subunit vaccine and preparation method thereof | |
| CN104693310A (en) | Chimeric protein, virus-like particle and application thereof | |
| CN105924506A (en) | Preparation method of bovine viral diarrhea virus E2 protein subunit vaccine | |
| CN104292339A (en) | Recombinant protein containing SARS virus RBD antigen and baculovirus displaying RBD protein | |
| CN102559614A (en) | Classical swine fever vaccine and preparation method thereof | |
| CN105039373A (en) | Recombinant plasmid, recombinant virus vector, recombinant virus strain and application thereof, recombinant protein and subunit vaccine containing the same | |
| CN101210248A (en) | ILTV gD glycoprotein nucleotide sequence and amino acid sequence, recombined virus bacterin thereof and application of the bacterin | |
| CN107779457A (en) | Vaccine combination and its preparation method and application | |
| CN104292338A (en) | Recombinant protein containing SARS virus N antigen and baculovirus displaying N protein | |
| CN102604993A (en) | Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof | |
| CN102363770A (en) | Recombinant baculovirus capable of expressing porcine circovirus type 2 Cap protein and somatostatin in fusion manner, and subunit vaccine thereof | |
| CN102533798B (en) | Recombinant denovirus for expressing foot-and-mouth disease virus type A empty capsid, and application thereof | |
| CN104293740A (en) | Recombinant baculovirus with surface displaying SARS bivalent antigen, and preparation method and application thereof | |
| CN102533678A (en) | Vivax malaria erythrocytic stage vaccine and preparation method thereof | |
| CN102747092A (en) | Recombinant defective adenoviruses expressing O type foot and mouth disease virus empty capsid, and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120711 |